NASDAQ · AQST
Aquestive Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AQST: Nov 03, 2026
Aquestive Therapeutics, Inc. Common Stock is expected to report earnings on 11/03/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.1. The reported EPS for the same quarter last year was $-0.14.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.10 | $-0.09 | $-0.11 | 2 |
| Dec 2026 | $-0.11 | $-0.09 | $-0.12 | 2 |
| Mar 2027 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Jun 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · MarketBeat · Zacks- RTTNews · Oct 15, 8:04 AM EDTAquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA Resubmission(RTTNews) – Aquestive Therapeutics, Inc. (AQST) announced that the U.S.FDA has accepted the resubmission of its New Drug Application for Anaphylm, a sublingual oral film for the treatment of severe allergic reactions, including anaphylaxis.
- RTTNews · Oct 15, 7:23 AM EDTAquestive Says FDA Accepts Anaphylm NDA Resubmission For The Treatment Of Type I Allergic Reactions(RTTNews) – Aquestive Therapeutics, Inc. (AQST), a biopharmaceutical company, announced Thursday that the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New Drug Application (NDA) for Anaphylm (dibutepinephrine) sublingual film for the treatment
- RTTNews · Oct 14, 8:15 AM EDTEton Licenses LIBERVANT For U.S. Seizure Rescue Market(RTTNews) – A cheek-administered seizure rescue therapy could soon provide patients and caregivers with another treatment option. Eton Pharmaceuticals (ETON) and Aquestive Therapeutics (AQST) have entered into an exclusive U.S. licensing and supply agreement for LIBERVANT (dizaep
- RTTNews · Sep 17, 7:16 AM EDTAquestive Therapeutics Resubmits NDA For Anaphylm Sublingual Film(RTTNews) – Aquestive Therapeutics (AQST) announced that it has resubmitted its New Drug Application to the FDA for Anaphylm sublingual film for the treatment of Type I allergic reactions, including anaphylaxis. The company said the resubmission is supported by positive topline h
- The Motley Fool · Aug 18, 7:31 PM EDTAquestive (AQST) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 12, 10:05 AM EDTAquestive Therapeutics Q2 Earnings Call HighlightsAquestive Therapeutics (NASDAQ:AQST) said it plans to resubmit its new drug application for Anaphylm, its epinephrine sublingual film candidate for type 1 allergic reactions including anaphylaxis, before the end of the third quarter after completing studies requested by the U.S.
- Zacks · Aug 11, 5:25 PM EDTAquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue EstimatesAquestive Therapeutics (AQST) delivered earnings and revenue surprises of -80.00% and +12.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Aug 10, 9:23 AM EDTAquestive Reports Positive Data For Anaphylm; Plans NDA Resubmission In Q3(RTTNews) – Aquestive Therapeutics, Inc. (AQST), a pharmaceutical company, announced positive topline results from human factors (HF) validation and pharmacokinetic (PK) studies evaluating Anaphylm sublingual film for the treatment of Type 1 allergic reactions, including anaphyla
- Zacks · Aug 6, 7:10 PM EDTGuardian Pharmacy Services (GRDN) Q2 Earnings and Revenues Top EstimatesGuardian Pharmacy (GRDN) delivered earnings and revenue surprises of +11.54% and +3.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 20, 7:26 AM EDTXencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Zacks · Jun 24, 7:32 AM EDTAquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- The Motley Fool · May 14, 2:18 PM EDTAQST Q1 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Aquestive Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.